SRZN News and Press, Surrozen Inc. From 01/04/23

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on Jan...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock It’s time to start the day with a look at the biggest pre-market stock movers traders need to know about on Thursday! Moving shares today are earnings reports, clinical trial data, a stock of...

Surrozen press release ( NASDAQ: SRZN ): Q3 GAAP EPS of -$0.38. Cash, cash equivalents and marketable securities for the third quarter ended September 30, 2022 were $78.4 million, compared to $92.7 million as of June 30, 2022. For further details see: Surrozen GA...

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported...

SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studies SZN-1326 preclinical data shows improved intestinal epithelial healing, restored epithelial barrier, and reduced colitis-associated c...

Surrozen ( NASDAQ: SRZN ) on Thursday said it had entered into a collaboration and licensing agreement with German pharmaceutical firm Boehringer Ingelheim for its antibody SZN-413 for the treatment of eye diseases. SRZN stock +12.5% to $2.43 in premarket trading. This...

The collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds in development Surrozen's novel antibody-based approach targets Fzd4 biology, which has been shown to play a fundamental role in retinal vascular integrity and functio...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Results highlight a potential novel treatment for diabetic and other retinopathies Unique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth into physiological regrowth of retinal blood vessels SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLO...

Surrozen press release ( NASDAQ: SRZN ): Q2 GAAP EPS of -$0.40 beats by $0.06 . Cash, cash equivalents and marketable securities for the Q2 were $92.7 million For further details see: Surrozen GAAP EPS of -$0.40 beats by $0.06